RenovoRx, Inc. (RNXT): Price and Financial Metrics


RenovoRx, Inc. (RNXT): $1.98

-0.02 (-1.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RNXT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RNXT Stock Price Chart Interactive Chart >

Price chart for RNXT

RNXT Price/Volume Stats

Current price $1.98 52-week high $16.74
Prev. close $2.00 52-week low $1.50
Day low $1.90 Volume 3,900
Day high $1.98 Avg. volume 69,321
50-day MA $2.29 Dividend yield N/A
200-day MA $0.00 Market Cap 17.95M

RenovoRx, Inc. (RNXT) Company Bio


RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California.


RNXT Latest News Stream


Event/Time News Detail
Loading, please wait...

RNXT Latest Social Stream


Loading social stream, please wait...

View Full RNXT Social Stream

Latest RNXT News From Around the Web

Below are the latest news stories about RenovoRx Inc that investors may wish to consider to help them evaluate RNXT as an investment opportunity.

RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in Ongoing TIGeR-PaC Phase 3 Clinical Trial

NEW YORK & LOS ALTOS, Calif., February 22, 2022--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced enrollment of its first patient at one of its newest clinical sites, Columbia University New York-Presbyterian Hospital Irving Medical Center ("Columbia University"), in its ongoing TIGeR-PaC Phase 3 clinical trial. The study is evaluating the Company’s therapy platform RenovoTAMP™ (RenovoRx Trans-Arter

Yahoo | February 22, 2022

RenovoRx to Host "Delivering Therapy Where it Matters" Fireside Chat with CEO, Shaun Bagai, on February 23rd at 12 P.M. ET

LOS ALTOS, Calif., February 03, 2022--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, will host the "Delivering Therapy Where it Matters" fireside chat with CEO, Shaun Bagai, on Wednesday, February 23rd at 12 p.m. ET.

Yahoo | February 3, 2022

RenovoRx Announces Presentation at the 2022 SPECTRUM Conference Highlighting Its Innovative RenovoTAMP™ Therapy for Targeted Treatment of Cancer

LOS ALTOS, Calif., January 19, 2022--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that Dr. Ripal Gandhi, M.D., FSIR, FSVM, a Principal Investigator in the Company’s Phase 3 TIGeR-PaC study, presented ‘Trans-arterial Treatment Option in Pancreas Cancer’ at the recent 2022 SPECTRUM Conference. Dr. Gandhi is professor of Interventional Radiology at the Miami Cancer Institute and Miami Cardiac and V

Yahoo | January 19, 2022

RenovoRx to Present at the H.C. Wainwright Bioconnect Virtual Conference

LOS ALTOS, Calif., January 06, 2022--RenovoRx, Inc. (NASDAQ: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that Shaun Bagai, Chief Executive Officer, will participate in the H.C. Wainwright Bioconnect Virtual Conference on behalf of RenovoRx. The conference will be held January 10-13, 2022.

Yahoo | January 6, 2022

Short Squeeze Stocks: PPSI, NUZE and 3 Others Experts Think Are Ready to Pop

PPSI, NUZE, and three other stocks are ranked highly in Fintel's Short Squeeze Screener.

Eddie Pan on InvestorPlace | November 29, 2021

Read More 'RNXT' Stories Here

RNXT Price Returns

1-mo 15.79%
3-mo -41.25%
6-mo -72.84%
1-year N/A
3-year N/A
5-year N/A
YTD -59.09%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7448 seconds.